nudt21 Antibody

What is NUDT21 and why is it important in molecular biology research?

NUDT21 (Nudix Hydrolase 21, also known as CFIm25 or Cpsf5) is a crucial component of the pre-mRNA cleavage and polyadenylation complex that regulates alternative polyadenylation (APA) . This 26 kDa protein plays essential roles in multiple biological processes including cell fate transitions, pluripotency maintenance, and differentiation . NUDT21 has emerged as a significant regulator in various cellular contexts, making it a valuable target for researchers studying RNA processing mechanisms, developmental biology, and disease pathology. The protein functions by binding to UGUA motifs near distal polyadenylation sites within the 3' UTR of target mRNAs, and its modulation can lead to widespread transcriptome changes affecting cellular phenotypes .

What are the main applications for NUDT21 antibodies in research?

NUDT21 antibodies have been validated for numerous research applications, providing versatile tools for investigating this protein's expression, localization, and interactions. Key applications include:

These applications have been documented across numerous published studies, indicating the reliability and versatility of NUDT21 antibodies in diverse experimental contexts .

What cell lines and tissues have been validated for NUDT21 antibody reactivity?

NUDT21 antibodies have been extensively validated across various experimental systems. For western blot applications, positive detection has been confirmed in HL-60 cells (human promyelocytic leukemia), NIH/3T3 cells (mouse fibroblasts), and MCF-7 cells (human breast adenocarcinoma) . Immunoprecipitation has been validated specifically in MCF-7 cells . For immunohistochemistry, human colon cancer tissue has shown reliable detection with NUDT21 antibodies, while immunofluorescence applications have been confirmed in HeLa cells (human cervical cancer) . Beyond these specific validations, research literature demonstrates reactivity in human neurons derived from WA09 (H9) embryonic stem cells, pancreatic adenocarcinoma tissues, and various other human and mouse model systems .

What are the optimal conditions for NUDT21 antibody use in Western Blotting?

For optimal Western Blot results with NUDT21 antibodies, follow these methodological guidelines:

• Sample preparation: Lyse cells in a buffer containing protease inhibitors to prevent degradation of NUDT21, which has an observed molecular weight of 26 kDa .

• Gel selection: 10-12% SDS-PAGE gels are recommended for optimal resolution of the 26 kDa NUDT21 protein.

• Antibody dilution: Use the NUDT21 antibody at a dilution of 1:2000-1:10000 depending on your specific experimental system and antibody lot . Begin with a middle dilution (1:5000) and adjust as needed.

• Blocking strategy: Use 5% non-fat dry milk or BSA in TBST for blocking (1 hour at room temperature).

• Incubation parameters: Primary antibody incubation is recommended overnight at 4°C with gentle agitation, followed by appropriate HRP-conjugated secondary antibody incubation.

• Expected band: Look for a specific band at 26 kDa, which has been consistently observed across multiple cell types including HL-60, NIH/3T3, and MCF-7 cells .

• Controls: Include positive controls such as lysates from MCF-7 cells where NUDT21 expression has been consistently detected , and consider knockdown or knockout samples as negative controls when available .

How should researchers optimize NUDT21 antibody protocols for immunohistochemistry?

When performing immunohistochemistry with NUDT21 antibodies, consider these technique-specific recommendations:

• Antigen retrieval: Two validated methods have shown success:

  • Primary recommendation: TE buffer pH 9.0 for optimal epitope exposure

  • Alternative method: Citrate buffer pH 6.0 may also be effective

• Antibody dilution: Use at 1:1000-1:4000 dilution, with preliminary titration recommended to determine optimal concentration for your specific tissue type .

• Incubation parameters: Overnight incubation at 4°C typically yields the best signal-to-noise ratio.

• Detection system: DAB-based chromogenic detection systems work well with this antibody.

• Validated tissues: Human colon cancer tissue has been specifically validated , while other studies have successfully used NUDT21 antibodies in pancreatic adenocarcinoma specimens and breast cancer tissues .

• Controls: Include both positive control tissues (colon cancer) and negative controls (primary antibody omission or isotype control) to validate staining specificity.

• Counterstaining: Hematoxylin counterstaining provides good nuclear contrast against NUDT21 immunostaining.

What are the recommended protocols for immunofluorescence experiments using NUDT21 antibodies?

For immunofluorescence detection of NUDT21:

• Cell fixation: 4% paraformaldehyde (15 minutes at room temperature) is recommended, followed by permeabilization with 0.2% Triton X-100 in PBS (10 minutes).

• Blocking: 5% normal serum (matched to secondary antibody host) with 0.1% BSA in PBS for 1 hour.

• Antibody dilution: Use NUDT21 antibody at 1:200-1:800 dilution in blocking buffer . Start with 1:400 and adjust as needed for optimal signal-to-noise ratio.

• Incubation parameters: Primary antibody incubation overnight at 4°C, followed by fluorophore-conjugated secondary antibody (typically 1:500-1:1000) for 1 hour at room temperature.

• Nuclear counterstain: DAPI (1:1000) for 5 minutes provides good nuclear reference.

• Mounting medium: Use anti-fade mounting medium to preserve fluorescence signal.

• Validated cells: HeLa cells have been specifically confirmed , but successful staining has been reported in multiple neuronal and cancer cell models .

• Expected pattern: NUDT21 shows predominantly nuclear localization with some cytoplasmic distribution, consistent with its role in RNA processing.

How can researchers effectively use NUDT21 antibodies for studying alternative polyadenylation mechanisms?

NUDT21 plays a central role in alternative polyadenylation (APA), making its antibodies valuable tools for investigating this critical RNA processing mechanism:

• Chromatin Immunoprecipitation (ChIP): NUDT21 antibodies can be used to identify genomic regions where NUDT21 regulates RNA processing. This technique has been validated in multiple publications and provides insight into the chromatin-associated functions of NUDT21.

• RNA Immunoprecipitation (RIP): Researchers can apply NUDT21 antibodies to isolate and identify NUDT21-bound RNA transcripts. The technique has been validated in publications and is particularly useful for identifying direct targets of NUDT21-mediated APA regulation.

• Combined approaches: For comprehensive analysis of NUDT21's role in APA:

  • Perform RIP-seq to identify NUDT21-bound transcripts

  • Combine with polyA site-sequencing (PAS-seq) before and after NUDT21 knockdown

  • Analyze the distribution of NUDT21 binding motif (UGUA) within the 3' UTR of target mRNAs

Studies have shown that NUDT21 suppression leads to a massive shift from distal to proximal polyA sites (1,562 transcripts affected) . Analysis revealed enrichment of UGUA motifs near distal polyA sites compared to proximal polyA sites specifically within NUDT21 target genes . This methodological approach can identify how NUDT21 regulates target transcript processing and subsequent protein expression changes that impact cellular phenotypes.

What experimental designs are recommended for investigating NUDT21's role in cell fate transitions?

NUDT21 has been identified as a regulator of cell fate transitions, particularly in pluripotency acquisition and differentiation. Researchers can apply these experimental approaches:

• Knockdown/knockout strategies:

  • siRNA-based knockdown: Use validated siRNAs targeting NUDT21 (produces transient effects suitable for acute phenotypes)

  • shRNA-based knockdown: For stable suppression, validated shRNAs like V2LHS_197948 and V2LHS_253272 have been used successfully in human cells

  • Confirm knockdown efficiency by Western blot using anti-NUDT21 antibodies (1:2000-1:10000 dilution)

• Pluripotency induction assays:

  • Combine NUDT21 knockdown with OKSM (Oct4, Klf4, Sox2, Myc) expression in fibroblasts

  • Assess reprogramming efficiency through alkaline phosphatase staining and transgene-independent colony formation

  • Monitor pluripotency marker expression (Nanog, Esrrb, Cdh1) by qPCR and immunostaining

• Differentiation assays:

  • Embryoid body (EB) formation with NUDT21-depleted embryonic stem cells

  • Measure EB size and morphology as indicators of differentiation potential

  • Analyze lineage-specific marker expression across ectoderm (Pax6, Sox1), mesoderm, and endoderm

  • Utilize immunofluorescence with NUDT21 antibodies (1:200-1:800 dilution) to track protein expression during differentiation

Research has demonstrated that NUDT21 suppression enhances reprogramming efficiency (30-fold increase in AP-positive colonies), accelerates pluripotency marker expression, and impairs differentiation, particularly toward the ectodermal lineage . These findings highlight the importance of NUDT21 in directing cell fate decisions through APA regulation.

How can NUDT21 antibodies be employed to investigate its role in cancer biology?

NUDT21 has emerging roles in cancer biology, with context-dependent functions across different malignancies. Researchers can implement these approaches:

• Expression analysis in tumor specimens:

  • Immunohistochemistry: Using NUDT21 antibodies (1:1000-1:4000 dilution) to assess protein expression in tumor versus normal tissues

  • Correlation with clinical parameters: Analyze association between NUDT21 expression and patient prognosis, tumor stage, or treatment response

  • Multi-marker panels: Combine with other cancer biomarkers for comprehensive tumor profiling

• Functional assessment in cancer cell models:

  • Manipulation of NUDT21 levels: Use overexpression or knockdown approaches in cancer cell lines

  • Phenotypic assays: Monitor changes in proliferation, migration, invasion, and apoptosis

  • Verify NUDT21 modulation by Western blotting (1:2000-1:10000 dilution)

• Mechanistic investigations:

  • Protein-protein interaction studies: Use NUDT21 antibodies for co-immunoprecipitation (CoIP) to identify cancer-relevant binding partners

  • Signaling pathway analysis: Examine how NUDT21 modulation affects key oncogenic pathways

  • APA profile changes: Connect NUDT21-mediated RNA processing alterations to cancer phenotypes

Recent studies revealed that NUDT21 is upregulated in pancreatic adenocarcinoma and correlates with diagnosis and prognosis . Mechanistically, NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway in pancreatic cancer . Conversely, in breast cancer, NUDT21 appears to play a tumor-suppressive role by inhibiting cell proliferation and invasion via the NUDT21/CPSF6 pathway . These contrasting findings highlight the complexity of NUDT21's role in cancer and the importance of careful experimental design when studying this protein in oncological contexts.

What are common problems encountered when using NUDT21 antibodies and how can they be resolved?

Researchers may encounter several technical challenges when working with NUDT21 antibodies:

• High background in Western blots:

  • Problem: Non-specific binding producing excessive background signal

  • Solution: Increase blocking time (2 hours), use alternative blocking agents (5% BSA instead of milk), increase wash steps (5x 5 minutes), and optimize antibody dilution (start with 1:5000)

• Weak or absent signal in immunohistochemistry:

  • Problem: Insufficient antigen retrieval or suboptimal antibody concentration

  • Solution: Compare antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0), extend retrieval time, and titrate antibody concentration within recommended range (1:1000-1:4000)

• Poor signal-to-noise ratio in immunofluorescence:

  • Problem: Non-specific binding or high autofluorescence

  • Solution: Include additional blocking steps (e.g., with 10% normal serum), reduce primary antibody concentration (try 1:500-1:800), and include autofluorescence quenching steps

• Multiple bands in Western blot:

  • Problem: Detection of splice variants, degradation products, or non-specific binding

  • Solution: Validate with NUDT21 knockdown controls, ensure fresh sample preparation with protease inhibitors, and optimize denaturing conditions

• Variable immunoprecipitation efficiency:

  • Problem: Inconsistent pull-down of NUDT21 complexes

  • Solution: Optimize antibody amount (0.5-4.0 μg for 1.0-3.0 mg of total protein), adjust lysis conditions to preserve protein interactions, and consider crosslinking approach for transient interactions

• Cross-reactivity concerns:

  • Problem: Potential detection of related proteins

  • Solution: Validate specificity using knockdown/knockout controls, compare results with alternative NUDT21 antibodies, and carefully select experimental systems where reactivity has been confirmed (human, mouse, rat)

How should researchers interpret complex data patterns when studying NUDT21 in different biological contexts?

NUDT21 functions can vary significantly across biological contexts, creating interpretation challenges:

• Context-dependent functions:

  • Challenge: NUDT21 shows apparently contradictory roles in different systems (e.g., cancer-promoting in pancreatic adenocarcinoma vs. tumor-suppressive in breast cancer )

  • Approach: Always include appropriate context-specific controls, avoid generalizing findings across tissues/diseases, and perform comprehensive literature review for your specific biological system

• APA regulation interpretation:

  • Challenge: Changes in APA may not translate directly to protein level changes

  • Approach: Combine polyA site analysis with protein quantification for key targets, focus on both direct (RNA processing) and indirect (downstream pathway) effects of NUDT21 modulation

• Distinguishing primary vs. secondary effects:

  • Challenge: NUDT21 affects numerous transcripts, making it difficult to identify key mediators

  • Approach: Perform time-course experiments, use rescue experiments with individual candidates, and employ systems biology approaches to map pathway interactions

• Temporal dynamics considerations:

  • Challenge: NUDT21's impact may vary across developmental stages or disease progression

  • Approach: Design longitudinal studies, analyze multiple timepoints during cellular transitions, and correlate with other stage-specific markers

• Integration with other RNA processing factors:

  • Challenge: NUDT21 functions as part of larger complexes (with CPSF6, etc.)

  • Approach: Consider co-immunoprecipitation studies to identify context-specific binding partners, analyze multiple complex components simultaneously, and account for compensatory mechanisms

Research has shown that NUDT21 suppression affects over 1,500 transcripts during cellular reprogramming, yet only a fraction show altered protein levels . Additionally, suppression of NUDT21 in embryonic stem cells impairs differentiation toward the ectodermal lineage while maintaining mesoderm and endoderm differentiation capacity . These complex patterns highlight the importance of comprehensive experimental design and cautious data interpretation.

What controls are essential when using NUDT21 antibodies in advanced research applications?

Robust experimental design requires appropriate controls when using NUDT21 antibodies:

• Antibody validation controls:

  • Positive controls: Include lysates/sections from tissues with confirmed NUDT21 expression (HL-60, NIH/3T3, MCF-7 cells for WB; human colon cancer tissue for IHC; HeLa cells for IF)

  • Negative controls:

    • Technical: Primary antibody omission, isotype control antibody

    • Biological: NUDT21 knockdown/knockout samples when available

• Knockdown validation controls:

  • Monitor knockdown efficiency at both RNA and protein levels

  • Include scrambled/non-targeting siRNA or shRNA controls

  • Assess potential off-target effects through rescue experiments

• Functional controls for mechanistic studies:

  • Pathway intervention: Include inhibitors of downstream pathways to confirm mechanism (e.g., PI3K/AKT inhibitors when studying NUDT21's role in this pathway)

  • Binding mutants: Use NUDT21 mutants with altered RNA binding capacity to distinguish binding-dependent from binding-independent functions

  • Domain-specific interventions: Target specific functional domains to dissect molecular mechanisms

• Context-specific controls:

  • Cell cycle analysis: Since APA can be influenced by proliferation state, include cell cycle assessments (e.g., CFSE assays, direct cell counting)

  • Apoptosis evaluation: Rule out cell death effects using appropriate assays (e.g., AnnexinV staining)

  • Differentiation markers: Include lineage-specific markers when studying developmental contexts

• Technical controls for specialized applications:

  • For ChIP: Include input control, IgG control, and positive control regions

  • For RIP: Non-specific IgG control and known non-target transcripts

  • For CoIP: Reciprocal IP and non-interacting protein controls

Research has demonstrated that NUDT21 knockdown enhances reprogramming independently of proliferation or apoptosis effects, as validated through CFSE assays, cell counting, and AnnexinV staining . Such comprehensive controls are essential for accurate interpretation of NUDT21 functional studies.

How can researchers leverage NUDT21 antibodies to investigate neurological disorders?

NUDT21 has emerging roles in neurological function and disease that researchers can explore:

• Neurodevelopmental applications:

  • Study NUDT21 expression patterns during neural differentiation using immunofluorescence (1:200-1:800 dilution)

  • Analyze consequences of NUDT21 modulation on neuronal maturation, morphology, and electrophysiological properties

  • Investigate interactions between NUDT21 and neurodevelopmental transcription factors using co-immunoprecipitation

• Learning and memory research:

  • Examine NUDT21 expression in different brain regions using immunohistochemistry (1:1000-1:4000)

  • Correlate NUDT21 levels with learning performance in animal models

  • Investigate activity-dependent regulation of NUDT21 in neuronal cultures

• Neurological disease models:

  • Compare NUDT21 expression between control and disease tissue/cells using Western blot (1:2000-1:10000)

  • Analyze APA profiles in neurological conditions using NUDT21 antibodies for RIP-seq

  • Test whether NUDT21 modulation affects disease-relevant phenotypes

Research has shown that partial loss of NUDT21 (Nudt21+/- mice) causes learning deficits and cortical hyperexcitability, along with misregulated alternative polyadenylation in the hippocampus . These findings suggest NUDT21 as a potential therapeutic target or biomarker for cognitive disorders. Human neurons with NUDT21 knockdown (using shRNAs V2LHS_197948 and V2LHS_253272) cultured for 60 days show altered phenotypes, providing a valuable model system for investigating NUDT21's neurological functions .

What emerging technologies can be combined with NUDT21 antibodies for comprehensive analysis of alternative polyadenylation?

Researchers can integrate advanced technologies with NUDT21 antibodies to gain deeper insights:

• Single-cell approaches:

  • Combine single-cell RNA-seq with NUDT21 modulation to reveal cell-type-specific APA regulation

  • Apply single-cell Western or mass cytometry with NUDT21 antibodies to correlate protein levels with cellular phenotypes

  • Utilize multiplexed immunofluorescence to examine NUDT21 co-expression with cell-type markers

• Spatial transcriptomics integration:

  • Correlate NUDT21 immunohistochemistry patterns with spatial APA profiles

  • Examine tissue-specific NUDT21 expression and function in complex organs

  • Analyze microenvironmental influences on NUDT21-mediated RNA processing

• CRISPR-based technologies:

  • Generate endogenously tagged NUDT21 (e.g., CRISPR knock-in of fluorescent tags)

  • Employ CRISPRi/CRISPRa for precise modulation of NUDT21 expression

  • Use domain-specific CRISPR editing to dissect NUDT21 functional regions

• Live-cell imaging approaches:

  • Visualize NUDT21 dynamics using antibodies for immunofluorescence validation combined with live-cell reporters

  • Track NUDT21-RNA interactions in real-time using proximity ligation assays

  • Examine NUDT21 localization changes during cellular responses

• Multi-omics integration:

  • Combine RIP-seq, ChIP-seq, and proteomics to build comprehensive NUDT21 regulatory networks

  • Correlate APA changes with epitranscriptomic modifications

  • Integrate NUDT21-regulated processes with metabolomic profiles

Research has identified over 1,500 transcripts showing altered APA upon NUDT21 knockdown during cellular reprogramming . These transcripts were enriched for chromatin regulators, and analysis revealed characteristic UGUA motif enrichment near distal polyA sites of target genes . These findings provide a foundation for applying advanced technologies to further dissect NUDT21's regulatory networks and functions.

How might NUDT21 antibodies contribute to the development of novel therapeutic approaches?

NUDT21 research has therapeutic implications that researchers can explore:

• Cancer therapy applications:

  • Utilize NUDT21 antibodies to assess expression in patient tumor samples for potential stratification

  • Investigate NUDT21-mediated regulation of oncogenes and tumor suppressors via APA

  • Target NUDT21-dependent pathways (e.g., PI3K/AKT in pancreatic cancer ) for combination therapies

• Regenerative medicine approaches:

  • Apply NUDT21 modulation to enhance reprogramming efficiency for therapeutic cell generation

  • Investigate NUDT21's role in tissue-specific stem cell function

  • Develop strategies to temporarily modify NUDT21 levels during stem cell differentiation protocols

• Neurological disorder interventions:

  • Address NUDT21-associated learning deficits through targeted approaches

  • Examine whether normalizing NUDT21 function can ameliorate cortical hyperexcitability

  • Develop biomarkers based on NUDT21-regulated APA profiles in neurological conditions

• Drug discovery applications:

  • Screen for compounds that modify NUDT21 activity or binding properties

  • Identify small molecules that affect NUDT21-mediated APA without altering protein levels

  • Develop targeted protein degradation approaches for context-specific NUDT21 modulation

• Diagnostic development:

  • Create diagnostic panels incorporating NUDT21 expression or activity assessment

  • Develop APA signature analysis for disease classification

  • Establish prognostic indicators based on NUDT21 pathway activation

Research has demonstrated context-specific roles for NUDT21 across different diseases - tumor-promoting in pancreatic adenocarcinoma but tumor-suppressive in breast cancer . These divergent functions highlight the importance of precision approaches when targeting NUDT21 for therapeutic purposes. Additionally, NUDT21's role in learning and neuronal function suggests potential applications in cognitive disorders , while its impact on cellular reprogramming indicates utility in regenerative medicine approaches .